Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation

Pharmazie

Volumn 65, Issue 6, 2010, Pages 421-428

  Buchwald, Peter ^a   Bocca, N ^a   Marzorati, S ^a   Hochhaus, G ^b   Bodor, N ^b   Stabler, C ^a,c   Kenyon, N S ^a,c   Inverardi, L ^a   Molano, R D ^a   Ricordi, C ^a,c   Pileggi, Antonello ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c University of Miami College of Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; LOTEPREDNOL ETABONATE; MICROSPHERE; POLY(DEXTRO LEVO LACTIC) ACID; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; COMPUTER MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STABILITY; EXPLORATORY RESEARCH; FEASIBILITY STUDY; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; NONHUMAN; OSMOTIC MINIPUMP; PANCREAS ISLET TRANSPLANTATION; RAT; SUSTAINED RELEASE FORMULATION; ALGORITHM; ANIMAL; BIOTECHNOLOGY; COMPUTER SIMULATION; DELAYED RELEASE FORMULATION; DRUG IMPLANT; FEMALE; HUMAN; IMMUNOLOGY; INSTRUMENTATION; KAPLAN MEIER METHOD; PREGNANCY; TISSUE DISTRIBUTION;

ALGORITHMS; ANDROSTADIENES; ANIMALS; BIOTECHNOLOGY; CELL TRANSPLANTATION; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FEASIBILITY STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; KAPLAN-MEIERS ESTIMATE; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; PREGNANCY; RATS; TISSUE DISTRIBUTION;

EID: 77955296944     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0525R     Document Type: Article

References (81)

1. Alejandro R, Barton FB, Hering BJ, Wease S (2008) 2008 Update from the Collaborative Islet Transplant Registry Transplantation 86: 1783-8.
2. Alejandro R, Feldman EC, Bloom AD, Kenyon NS (1989) Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 38: 698-703. (Pubitemid 19285721)
3. Alejandro R, Latif Z, Polonsky KS, Shienvold FL, Civantos F, Mintz DH (1988) Natural history of multiple intrahepatic canine islet allografts during and following administration of cyclosporine. Transplantation 45: 1036-1044.
4. Alessiani M, Regazzi M, Abbiati F, Ferrari P, Molinaro M, Iacona I, Klersy C, Viezzoli A, Fayer F, Pileggi A, Zitelli E, Burroni B, Scandone M, Dionigi P, Zonta A. (2000) Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus Transplant Proc 32: 1214-1215.
5. Arck PC, Gilhar A, Bienenstock J, Paus R (2008) The alchemy of immune privilege explored from a neuroimmunological perspective. Curr Opin Pharmacol 8: 480-489.
6. Bell E, Cao X, Moibi JA, Greene SR, Young R, Trucco M, Gao Z, Matschinsky FM, Deng S, Markman JF, Naji A, Wolf BA (2003) Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52: 2731-2739. (Pubitemid 37339702)
7. Berman DM, O'Neil JJ, Coffey LC, Chaffanjon PC, Kenyon NM, Ruiz P Jr, Pileggi A, Ricordi C, Kenyon NS (2009) Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant 9: 91-104.
8. Bocca N, Buchwald P, Molano RD, et al. (2009) Biohybrid devices and local immunomodulation as opposed to systemic immunosuppression. In: Hallé JP, de Vos P, Rosenberg L (eds), The Bioartificial Pancreas and Other Biohybrid Therapies. Trivandrum, India: Research Signpost, p 309-328.
9. Bocca N, Pileggi A, Molano RD, Marzorati S, Wu W, Bodor N, Ricordi C, Buchwald P (2008) Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate in islet transplantation. Pharmazie 63: 226-232. (Pubitemid 351449934)
10. Bocca N, Ricordi C, Kenyon NS, Latta P, Buchwald P (2007) 3-D Multiphysics FEM modeling to optimize local drug delivery in a biohybrid device designed for cell transplant. In: Dravid V (ed), Proceedings of the COMSOL Conference 2007 Boston. Boston: COMSOL, Inc., p 101-107.
11. Bodor N, Buchwald P (2000) Soft drug design: general principles and recent applications. Med Res Rev 20: 58-101. (Pubitemid 30027561)
12. Bodor N, Buchwald P (2006) Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 12: 3241-3260. (Pubitemid 44375467)
13. Bodor N, Buchwald P (2008) Retrometabolic drug design: principles and recent developments. Pure Appl Chem 80: 1669-1682.
14. Buchwald P (2007) Computer-aided retrometabolic drug design: soft drugs. Expert Opin Drug Discov 2: 923-933.
15. Buchwald P (2008) Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids 73: 193-208.
16. Buchwald P (2009) FEM-based oxygen consumption and cell viability models for avascular pancreatic islets. Theor Biol Med Model 6: art. 5.
17. Buchwald P, Bodor N (2004) Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Pharmazie 59: 396-404. (Pubitemid 38720350)
18. Buchwald P, Margolles-Clark E, Kenyon NS, Ricordi C (2010) Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction. J Mol Recognit 23: 65-73.
19. Desai NM, Goss JA, Deng S, Wolf BA, Markmann E, Palanjian M, Shock AP, Feliciano S, Brunicardi FC, Barker CF, Naji A, Markmann JF (2003) Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 76: 1623-1625.
20. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA (2004) Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J. Ocul. Pharmacol. Ther. 20: 269-275.
21. Druzgala P, Hochhaus G, Bodor N (1991) Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J. Steroid Biochem. 38: 149-154.
22. Egidi FM (2005) Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer? Drugs 65: 153-166.
23. Faustman DL, Davis M (2009) The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J. Mol. Med.: ePub.
24. Fernandez LA, Lehmann R, Luzi L Battezzati A, Angelico MC, Ricordi C, Tzakis A, Alejandro R (1999) The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 68: 1532-1541.
25. First MR (2003) Posttransplant diabetes mellitus. Transplantation 75: 1769.
26. Fort A, Fort N, Ricordi C, Stabler CL (2008) Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas. Cell Transplant. 17: 997-1003.
27. Freise CE, Clemmings S, Clemens LE, Alan T, Ashby T, Ashby E, Burke EC, Roberts JP, Ascher NL (1991) Demonstration of local immunosuppression with methylprednisolone in the sponge matrix allograft model. Transplantation 52: 318-325.
28. Furtado A, Perdigoto R, Oliveira F, Geraldes B, Furtado E, Tomé L, Mota O, Ferrão J, Viana J, Bento C, Vieira H, Neves S (2000) Local immunosuppression in clinical small bowel transplantation (report of two cases). Transplant Proc 32: 1206-1208.
29. Galletti PM, Colton CK, Jaffrin M, Reach G (2006) Artificial pancreas. In: Bronzino JD (ed), The Biomedical Engineering Handbook. Tissue Engineering and Artificial Organs, 3rd ed. Boca Raton, FL: CRC Press, p 71.1-71.18.
30. Green EA, Flavell RA (1999) The initiation of autoimmune diabetes. Curr. Opin. Immunol. 11: 663-669.
31. Gruber SA (1992) Locoregional immunosuppression of organ transplants. Immunol. Rev. 129: 5-30.
32. Inceoglu S, Siemionow M, Chick L, Craven CM, Lister GD (1994) The effect of combined immunosuppression with systemic low-dose cyclosporin and topical fluocinolone acetonide on the survival of rat hind-limb allografts. Ann. Plast. Surg. 33: 57-65.
33. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P (2005) Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112: 1192-1198.
34. Kizilel S, Garfinkel M, Opara E (2005) The bioartificial pancreas: progress and challenges. Diabetes Technol. Ther. 7: 968-985.
35. Knisely TL, Hosoi J, Nazareno R, Granstein RD (1994) The presence of biologically significant concentrations of glucocorticoids but little or no cortisol binding globulin within aqueous humor: relevance to immune privilege in the anterior chamber of the eye. Invest. Ophthalmol. Vis. Sci. 35: 3711-3723.
36. Lai CC, Gouras P, Doi K, Tsang SH, Goff SP, Ashton P (2000) Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer. Invest. Ophthalmol. Vis. Sci. 41: 3134-3141.
37. Lambillotte C, Gilon P, Henquin JC (1997) Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J. Clin. Invest. 99: 414-423.
38. Leung A, Lawrie G, Nielsen LK, Trau M (2008) Synthesis and characterization of alginate/poly-L-ornithine/alginate microcapsules for local immunosuppression. J. Microencapsul. 25: 387-398.
39. Li X, Jast BR (2006) Design of Controlled Release Drug Delivery Systems. New York: McGraw-Hill.
40. Marcelli-Tourvieille S, Hubert T, Moerman E, Gmyr V, Kerr-Conte J, Nunes B, Dherbomez M, Vandewalle B, Pattou F, Vantyghem MC (2007) In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation 83: 532-538.
41. Margolles-Clark E, Umland O, Kenyon NS, Ricordi C, Buchwald P (2009) Small molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction. J Mol Med 87: 1133-1143.
42. Marzorati S, Bocca N, Molano RD, Hogan AR, Doni M, Cobianchi L, Inverardi L, Ricordi C, Pileggi A (2009a) Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. Transplant Proc 41: 352-353.
43. Marzorati S, Bocca N, Molano RD, et al. (2009b) Prolonged survival and function of allogeneic islets into a prevascularized, subcutaneous biohybrid device: Effects of the immunosuppressive regimen. (Abstr.) Am J Transplant 9 (Suppl. 2): 667.
44. Marzorati S, Pileggi A, Ricordi C (2007) Allogeneic islet transplantation Expert Opin Biol Ther 7: 1627-45.
45. Matzinger P (1994) Tolerance, danger, and the extended family Annu Rev Immunol 12: 991-1045.
46. Mellor AL, Munn DH (2008) Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8: 74-80.
47. Mineo D, Pileggi A, Alejandro R, Ricordi C (2009) Point: steady progress and current challenges in clinical islet transplantation Diabetes Care 32: 1563-9.
48. Nanji SA, Shapiro AM (2004) Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs 18: 315-328. (Pubitemid 39381948)
49. Narang AS, Mahato RI (2006) Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 58: 194-243. (Pubitemid 43752633)
50. Niederkorn JY (2006) See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 7: 354-359.
51. Noble S, Goa KL (1998) Loteprednol etabonate. Clinical potential in the management of ocular inflammation. BioDrugs 10: 329-339.
52. Okada H, Toguchi H (1995) Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12: 1-99.
53. Ozcay N, Fryer J, Grant D, Freeman D, Garcia B, Zhong R (1997) Budesonide, a locally acting steroid, prevents graft rejection in a rat model of intestinal transplantation. Transplantation 63: 1220-1225. (Pubitemid 27212814)
54. Pagano G, Cavallo-Perin P, Cassader M, et al. (1983) An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 72: 1814-1820.
55. Pavesio CE, Decory HH (2008) Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 92: 455-459.
56. Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29: 119-121. (Pubitemid 16162755)
57. Pileggi A, Alejandro R, Ricordi C (2006a) Islet transplantation: Steady progress and current challenges. Curr Opin Organ Transplant. 11: 7-13. (Pubitemid 43315675)
58. Pileggi A, Cobianchi L, Inverardi L, Ricordi C (2006b) Overcoming the challenges nowlimiting islet transplantation: a sequential, integrated approach Ann N Y Acad Sci 1079: 383-98. (Pubitemid 43315675)
59. Pileggi A, Molano RD, Ricordi C, et al. (2006c) Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation 81: 1318-1324. (Pubitemid 43804553)
60. Pinto E (2008) Sustained release of a soft glucocorticoid loteprednol etabonate using PLA microspheres for the prevention of islet transplantation rejection. (Ph.D. Thesis), College of Pharmacy, Vol Ph.D. Gainesville, FL: University of Florida, pp 121.
61. Pinto E, Zhang B, Song S, Bodor N, Buchwald P, Hochhaus G (2010) Feasibility of localized immunosuppression, 2.: PLA microspheres for the sustained local delivery of a soft immunosuppressant. Pharmazie 65: 429-435. (doi: 10.1691/ph.2010.0033R).
62. Qi D, Rodrigues B (2007) Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 292: E654-E667. (Pubitemid 46411042)
63. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA (2006) In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles J Control Release 112: 26-34.
64. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, Lee LK, Swartz MA, Hubbell JA (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat Biotechnol 25: 1159-64.
65. Ricordi C, Inverardi L, Kenyon NS, Goss J, Bertuzzi F, Alejandro R (2005) Requirements for success in clinical islet transplantation. Transplantation 79: 1298-1300. (Pubitemid 40734788)
66. Ricordi C, Strom TB (2004) Clinical islet transplantation: advances and immunological challenges Nat Rev Immunol 4: 259-68.
67. Ricordi C, Zeng Y, Alejandro R, Tzakis A, Carroll P, Rilo HL, Venkataramanan R, Fung JJ, Bereiter D, Starzl TE (1992) Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. Transplant Proc 24: 1042.
68. Rilo HL, Carroll PB, Zeng YJ, Fontes P, Demetris J, Ricordi C (1994) Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone. Transplantation 57: 181-187. (Pubitemid 24048581)
69. Ruers TJM, Buurman WA, Smits JFM, van der Linden CJ, van Dongen JJ, Struyker-Boudier HA, Kootstra G (1986) Local treatment of renal allografts, a promising way to reduce the dosage of immunosuppressive drugs. Comparison of various ways of administering prednisolone. Transplantation 41: 156-161.
70. Ruers TJM, Daemen MJAP, Thijssen HHW, van der Linden CJ, Buurman WA (1988) Sensitivity of graft rejection in rats to local immunosuppressive therapy. Transplantation 46: 820-825.
71. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, Fukushima Y, Onishi Y, Ono H, Fujishiro M, Kikuchi M, Oka Y, Asano T (2000) Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 49: 1700-1708.
72. Saltzman WM, Olbricht WL (2002) Building drug delivery into tissue engineering. Nat Rev Drug Discov 1: 177-186. (Pubitemid 37361421)
73. Shirbacheh MV, Jones JW, Breidenbach WC, McCabe S, Barker JH, Gruber SA (1998) The case for local immunosuppression in composite tissue allotransplantation. Transplant Proc 30: 2739-2742.
74. Solari MG, Washington KM, Sacks JM, Hautz T, Unadkat JV, Horibe EK, Venkataramanan R, Larregina AT, Thomson AW, Lee WP (2009) Daily topical tacrolimus therapy prevents skin rejection in a rodent hind limb allograft model. Plast Reconstr Surg 123: 17S-25S.
75. Thomas FT, Contreras JL, Bilbao G, Ricordi C, Curiel D, Thomas JM (1999) Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation Surgery 126: 299-304.
76. Waldmann H, Cobbold S (2004) Exploiting tolerance processes in transplantation. Science 305: 209-212.
77. Wang X, Alfrey EJ, Posselt A, Tafra L, Alak AM, Dafoe DC (1995) Intraportal delivery of immunosuppression to intrahepatic islet allograft recipients. Transpl Int 8: 268-272.
78. Weber T, Kalbhenn T, Herrmann G, Hanisch E (1997) Local immunosuppression with budesonide after liver transplantation in the rat: a preliminary histomorphological analysis. Transplantation 64: 705-708.
79. Zahr E, Molano RD, Pileggi A, Ichii H, Jose SS, Bocca N, An W, Gonzalez-Quintana J, Fraker C, Ricordi C, Inverardi L (2007) Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 84: 1576-1583.
80. Zawalich WS, Tesz GJ, Yamazaki H, Zawalich KC, Philbrick W (2006) Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets. Metabolism 55: 35-42.
81. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, Bromberg JS, Dong HH (2006) Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 55: 2429-2436.